🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma NCT06558604Phase 216 sites📍 Bruges📍 Brussels📍 Liège The Lymphoma Academic Research Organisation · Tests: Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07578077Phase 1, Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Golcadomide A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07377578Phase 32 sites📍 Beijing📍 Nanning Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Orelabrutinib Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) NCT07082686Phase 229 sites📍 Hefei📍 Beijing📍 Chengdu Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-248 BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites📍 Duarte📍 Stanford📍 Kansas City PeproMene Bio, Inc. · Tests: BAFFR-CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520Phase 1, Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762Phase 11 site📍 San Francisco C. Babis Andreadis · Tests: Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT06675123Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, BTK Inhibitor Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT06054776Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma NCT06252675Phase 24 sites📍 Davis📍 Los Angeles📍 San Diego University of California, San Francisco · Tests: Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients NCT05098613Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T Cells Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT05910801Phase 22 sites📍 Rochester📍 Houston Academic and Community Cancer Research United · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies NCT06980116Phase 117 sites📍 Tbilisi📍 Athens📍 Pátrai Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: EXS73565 Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745Phase 14 sites📍 Durham📍 Cincinnati📍 Columbus Newave Pharmaceutical Inc · Tests: LP-168, LP-168 Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07460362Phase 21 site📍 Beijing Peking University Third Hospital · Tests: Glofitamab, Lenalidomide Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL NCT06553872Phase 23 sites📍 Stanford📍 Miami📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Pirtobrutinib, Brexucabtagene Autoleucel A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742Phase 1, Phase 27 sites📍 Westwood📍 St Louis📍 San Antonio CRISPR Therapeutics AG · Tests: CTX112 B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies NCT06191887Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489Phase 232 sites📍 Birmingham📍 Gilbert📍 Phoenix Miltenyi Biomedicine GmbH · Tests: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy